|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Dela Cruz CS, Tanoue LT and Matthay RA:
Lung cancer: Epidemiology, etiology, and prevention. Clin Chest
Med. 32:605–644. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Choi CM: Overview of ALK and ROS1
rearranged lung cancer. Tuberc Respir Dis (Seoul). 75:236–237.
2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Kim J, Jang SJ, Choi CM and Ro JY:
Correlation of histologic subtypes and molecular alterations in
pulmonary adenocarcinoma: Therapeutic and prognostic implications.
Adv Anat Pathol. 23:330–338. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ou SH, Chalmers ZR, Azada MC, Ross JS,
Stephens PJ, Ali SM and Miller VA: Identification of a novel
TMEM106B-ROS1 fusion variant in lung adenocarcinoma by
comprehensive genomic profiling. Lung Cancer. 88:352–354.
2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Kohno T, Ichikawa H, Totoki Y, Yasuda K,
Hiramoto M, Nammo T, Sakamoto H, Tsuta K, Furuta K, Shimada Y, et
al: KIF5B-RET fusions in lung adenocarcinoma. Nat Med. 18:375–377.
2012.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Ding X, Zhang Z, Jiang T, Li X, Zhao C, Su
B and Zhou C: Clinicopathologic characteristics and outcomes of
Chinese patients with non-small-cell lung cancer and BRAF mutation.
Cancer Med. 6:555–562. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Chen Z, Liu X, Zhao J, Yang H and Teng X:
Correlation of EGFR mutation and histological subtype according to
the IASLC/ATS/ERS classification of lung adenocarcinoma. Int J Clin
Exp Pathol. 7:8039–8045. 2014.PubMed/NCBI
|
|
9
|
Travis WD, Brambilla E, Noguchi M,
Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ,
Van Schil PE, et al: International association for the study of
lung cancer/american thoracic society/european respiratory society
international multidisciplinary classification of lung
adenocarcinoma. J Thorac Oncol. 6:244–285. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Warth A, Muley T, Meister M, Stenzinger A,
Thomas M, Schirmacher P, Schnabel PA, Budczies J, Hoffmann H and
Weichert W: The novel histologic international association for the
study of lung cancer/American thoracic society/European respiratory
society classification system of lung adenocarcinoma is a
stage-independent predictor of survival. J Clin Oncol.
30:1438–1446. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Russell PA, Wainer Z, Wright GM, Daniels
M, Conron M and Williams RA: Does lung adenocarcinoma subtype
predict patient survival?: A clinicopathologic study based on the
new international association for the study of lung cancer/American
thoracic society/European respiratory society international
multidisciplinary lung adenocarcinoma classification. J Thorac
Oncol. 6:1496–1504. 2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Villa C, Cagle PT, Johnson M, Patel JD,
Yeldandi AV, Raj R, DeCamp MM and Raparia K: Correlation of EGFR
mutation status with predominant histologic subtype of
adenocarcinoma according to the new lung adenocarcinoma
classification of the international association for the study of
lung cancer/American thoracic society/European respiratory society.
Arch Pathol Lab Med. 138:1353–1357. 2014.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Pan Y, Zhang Y, Li Y, Hu H, Wang L, Li H,
Wang R, Ye T, Luo X, Zhang Y, et al: ALK, ROS1 and RET fusions in
1139 lung adenocarcinomas: A comprehensive study of common and
fusion pattern-specific clinicopathologic, histologic and cytologic
features. Lung Cancer. 84:121–126. 2014.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Kim YH, Ishii G, Goto K, Nagai K, Tsuta K,
Shiono S, Nitadori J, Kodama T, Nishiwaki Y and Ochiai A: Dominant
papillary subtype is a significant predictor of the response to
gefitinib in adenocarcinoma of the lung. Clin Cancer Res.
10:7311–7317. 2004.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Reck M, Rodríguez-Abreu D, Robinson AG,
Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe
S, et al: KEYNOTE-024 Investigators: Pembrolizumab versus
chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl
J Med. 375:1823–1833. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Lin SY, Yang CY, Liao BC, Ho CC, Liao WY,
Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, et al: Tumor PD-L1
expression and clinical outcomes in advanced-stage non-small cell
lung cancer patients treated with nivolumab or pembrolizumab:
Real-world data in Taiwan. J Cancer. 9:1813–1820. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Herbst RS, Baas P, Kim DW, Felip E,
Pérez-Gracia JL, Han JY, Molina J, Kim JH, Arvis CD, Ahn MJ, et al:
Pembrolizumab versus docetaxel for previously treated,
PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010):
A randomised controlled trial. Lancet. 387:1540–1550.
2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Rittmeyer A, Barlesi F, Waterkamp D, Park
K, Ciardiello F, von Pawel J, Gadgeel SM, Hida T, Kowalski DM, Dols
MC, et al: OAK study group. Atezolizumab versus docetaxel in
patients with previously treated non-small-cell lung cancer (OAK):
A phase 3, open-label, multicentre randomised controlled trial.
Lancet. 389:255–265. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287.
2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
He J, Hu Y, Hu M and Li B: Development of
PD-1/PD-L1 pathway in tumor immune microenvironment and treatment
for non-small cell lung cancer. Sci Rep. 5(13110)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sorensen SF, Zhou W, Dolled-Filhart M,
Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M,
Meldgaard P and Hager H: PD-L1 expression and survival among
patients with advanced non-small cell lung cancer treated with
chemotherapy. Transl Oncol. 9:64–69. 2016.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Wang A, Wang HY, Liu Y, Zhao MC, Zhang HJ,
Lu ZY, Fang YC, Chen XF and Liu GT: The prognostic value of PD-L1
expression for non-small cell lung cancer patients: A
meta-analysis. Eur J Surg Oncol. 41:450–456. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Velcheti V, Schalper KA, Carvajal DE,
Anagnostou VK, Syrigos KN, Sznol M, Herbst RS, Gettinger SN, Chen L
and Rimm DL: Programmed death ligand-1 expression in non-small cell
lung cancer. Lab Invest. 94:107–116. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Incorvaia L, Fanale D, Badalamenti G,
Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A,
Vieni S, et al: Programmed death ligand 1 (PD-L1) as a predictive
biomarker for pembrolizumab therapy in patients with advanced
non-small-cell lung cancer (NSCLC). Adv Ther. 36:2600–2617.
2019.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Heymann JJ, Bulman WA, Swinarski D, Pagan
CA, Crapanzano JP, Haghighi M, Fazlollahi L, Stoopler MB, Sonett
JR, Sacher AG, et al: PD-L1 expression in non-small cell lung
carcinoma: Comparison among cytology, small biopsy, and surgical
resection specimens. Cancer Cytopathol. 125:896–907.
2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Zhang Y, Wang L, Li Y, Pan Y, Wang R, Hu
H, Li H, Luo X, Ye T, Sun Y and Chen H: Protein expression of
programmed death 1 ligand 1 and ligand 2 independently predict poor
prognosis in surgically resected lung adenocarcinoma. Onco Targets
Ther. 7:567–573. 2014.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Dako: PD-L1 IHC 22C3 pharmDx. https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150013S014C.pdf.
|
|
29
|
Wang T, Zhang Y, Liu B, Hu M, Zhou N and
Zhi X: Associations between epidermal growth factor receptor
mutations and histological subtypes of lung adenocarcinoma
according to the IASLC/ATS/ERS classification in Chinese patients.
Thorac Cancer. 8:600–605. 2017.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Li H, Pan Y, Li Y, Li C, Wang R, Hu H,
Zhang Y, Ye T, Wang L, Shen L, et al: Frequency of well-identified
oncogenic driver mutations in lung adenocarcinoma of smokers varies
with histological subtypes and graduated smoking dose. Lung Cancer.
79:8–13. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Yoshizawa A, Sumiyoshi S, Sonobe M,
Kobayashi M, Fujimoto M, Kawakami F, Tsuruyama T, Travis WD, Date H
and Haga H: Validation of the IASLC/ATS/ERS lung adenocarcinoma
classification for prognosis and association with EGFR and KRAS
gene mutations: Analysis of 440 Japanese patients. J Thorac Oncol.
8:52–61. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Dong YJ, Cai YR, Zhou LJ, Su D, Mu J, Chen
XJ and Zhang LI: Association between the histological subtype of
lung adenocarcinoma, EGFR/KRAS mutation status and the ALK
rearrangement according to the novel IASLC/ATS/ERS classification.
Oncol Lett. 11:2552–2558. 2016.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Marchetti A, Buttitta F, Pellegrini S,
Chella A, Bertacca G, Filardo A, Tognoni V, Ferreli F, Signorini E,
Angeletti CA and Bevilacqua G: Bronchioloalveolar lung carcinomas:
K-ras mutations are constant events in the mucinous subtype. J
Pathol. 179:254–259. 1996.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Kadota K, Yeh YC, D'Angelo SP, Moreira AL,
Kuk D, Sima CS, Riely GJ, Arcila ME, Kris MG, Rusch VW, et al:
Associations between mutations and histologic patterns of mucin in
lung adenocarcinoma: Invasive mucinous pattern and extracellular
mucin are associated with KRAS mutation. Am J Surg Pathol.
38:1118–1127. 2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang M, Li G and Wang Y and Wang Y, Zhao
S, Haihong P, Zhao H and Wang Y: PD-L1 expression in lung cancer
and its correlation with driver mutations: A meta-analysis. Sci
Rep. 7(10255)2017.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Pan ZK, Ye F, Wu X, An HX and Wu JX:
Clinicopathological and prognostic significance of programmed cell
death ligand1 (PD-L1) expression in patients with non-small cell
lung cancer: A meta-analysis. J Thorac Dis. 7:462–470.
2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Yang H, Chen H, Luo S, Li L, Zhou S, Shen
R, Lin H and Xie X: The correlation between programmed death-ligand
1 expression and driver gene mutations in NSCLC. Oncotarget.
8:23517–23528. 2017.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Pan Y, Zheng D, Li Y, Cai X, Zheng Z, Jin
Y, Hu H, Cheng C, Shen L, Wang J, et al: Unique distribution of
programmed death ligand 1 (PD-L1) expression in East Asian
non-small cell lung cancer. J Thorac Dis. 9:2579–2586.
2017.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Miyazawa T, Marushima H, Saji H, Kojima K,
Hoshikawa M, Takagi M and Nakamura H: PD-L1 expression in
non-small-cell lung cancer including various adenocarcinoma
subtypes. Ann Thorac Cardiovasc Surg. 25:1–9. 2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Driver BR, Miller RA, Miller T, Deavers M,
Gorman B, Mody D, Ge Y, Barrios R, Bernicker E, Kim M and Cagle PT:
Programmed death ligand-1 (PD-L1) expression in either tumor cells
or tumor-infiltrating immune cells correlates with solid and
high-grade lung adenocarcinomas. Arch Pathol Lab Med.
141:1529–1532. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Song P, Wu S, Zhang L, Zeng X and Wang J:
Correlation between PD-L1 expression and clinicopathologic features
in 404 patients with lung adenocarcinoma. Interdiscip Sci.
11:258–265. 2019.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Dong ZY, Zhang C, Li YF, Su J, Xie Z, Liu
SY, Yan LX, Chen ZH, Yang XN, Lin JT, et al: Genetic and immune
profiles of solid predominant lung adenocarcinoma reveal potential
immunotherapeutic strategies. J Thorac Oncol. 13:85–96.
2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Sul J, Blumenthal GM, Jiang X, He K,
Keegan P and Pazdur R: FDA approval summary: Pembrolizumab for the
treatment of patients with metastatic non-small cell lung cancer
whose tumors express programmed death-ligand. Oncologist.
21:643–650. 2016.PubMed/NCBI View Article : Google Scholar
|
